|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
49,450,000 |
Market
Cap: |
1.52(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$25.5 - $42.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 623 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
119,323 |
119,323 |
189,781 |
290,198 |
Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,334,261 |
$12,063,571 |
Total People Sold |
1 |
1 |
15 |
16 |
Total Sell Transactions |
3 |
3 |
34 |
58 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Riker Lauren Bullaro |
Vice President, Finance |
|
2020-08-11 |
4 |
OE |
$10.34 |
$84,581 |
D/D |
8,180 |
20,813 |
|
- |
|
Wicki Andreas |
Director |
|
2020-08-11 |
4 |
S |
$60.87 |
$6,546,747 |
I/I |
(106,772) |
843,590 |
|
2% |
|
Laranjeira Charles Anthony |
SVP, Technical Operations |
|
2020-08-03 |
4 |
AS |
$52.68 |
$131,700 |
D/D |
(2,500) |
20,796 |
|
7% |
|
Laranjeira Charles Anthony |
SVP, Technical Operations |
|
2020-08-03 |
4 |
OE |
$44.10 |
$110,250 |
D/D |
2,500 |
22,750 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2020-07-15 |
4 |
AS |
$56.88 |
$682,560 |
D/D |
(12,000) |
188,377 |
|
12% |
|
Laranjeira Charles Anthony |
SVP, Technical Operations |
|
2020-06-29 |
4 |
AS |
$50.01 |
$3,021,314 |
D/D |
(60,101) |
20,250 |
|
10% |
|
Laranjeira Charles Anthony |
SVP, Technical Operations |
|
2020-06-29 |
4 |
OE |
$37.81 |
$2,366,588 |
D/D |
56,250 |
80,351 |
|
- |
|
Riker Lauren Bullaro |
Vice President, Finance |
|
2020-06-29 |
4 |
AS |
$48.72 |
$296,800 |
D/D |
(6,000) |
12,633 |
|
10% |
|
Riker Lauren Bullaro |
Vice President, Finance |
|
2020-06-29 |
4 |
OE |
$10.34 |
$62,040 |
D/D |
6,000 |
18,633 |
|
- |
|
Longenecker John P Phd |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
17,757 |
|
- |
|
Brege Laura |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
7,921 |
|
- |
|
Pace Gary W |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
59,949 |
|
- |
|
Froimson Mark |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
5,976 |
|
- |
|
Greenstreet Yvonne |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
11,021 |
|
- |
|
Hastings Paul J |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
6,116 |
|
- |
|
Kronenfeld Mark A. |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
15,671 |
|
- |
|
Christie Christopher |
Director |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
1,260 |
|
- |
|
Reinhardt Max |
President |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
14,000 |
|
- |
|
Mcloughlin Dennis |
Chief Commercial Officer |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
28,898 |
|
- |
|
Reinhart Charles A. Iii |
Chief Financial Officer |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
12,600 |
27,447 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
33,300 |
200,209 |
|
- |
|
Winston Roy |
Chief Clinical Officer |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
39,237 |
|
- |
|
Dunker Kristen Marie |
Chief Administrative Officer |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
24,887 |
|
- |
|
Riker Lauren Bullaro |
Vice President, Finance |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
12,633 |
|
- |
|
Laranjeira Charles Anthony |
SVP, Technical Operations |
|
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
24,101 |
|
- |
|
781 Records found
|
|
Page 11 of 32 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|